Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis.
Protective Autoimmunity: A Unifying Model for the Immune Network Involved in CNS Repair.
Automated reference region extraction and population-based input function for brain [(11)C]TMSX PET image analyses.
Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis.
Impact of anger on the health-related quality of life of multiple sclerosis patients.
Correction: Cerebral Circulation Time is Prolonged and Not Correlated with EDSS in Multiple Sclerosis Patients: A Study Using Digital Subtracted Angiography.
Directed Differentiation of Oligodendrocyte Progenitor Cells From Mouse Induced Pluripotent Stem Cells.
Impact of the environment on multiple sclerosis.
Multiple sclerosis and susceptibility to cardiovascular diseases: Implications of ethnicity-related interleukin-17A gene polymorphism?
Vitamin D as a protective factor in multiple sclerosis.
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
Is the CCR5 Δ 32 Mutation Associated with Immune System-Related Diseases?
[The effect of genetic factors on the phenotypic expression of multiple sclerosis.]
Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination.
N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
Pilot Trial of a Social Cognitive Theory-Based Physical Activity Intervention Delivered by Non-Supervised Technology in Persons With Multiple Sclerosis.
Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function.
Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis.
Epidemiology and clinical record of multiple sclerosis in selected countries - a systematic review.
Relapsing optic neuritis: a multicentre study of 62 patients.
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: From structural insights to post-transcriptional regulatory roles.
Pages
« first
‹ previous
…
446
447
448
449
450
451
452
453
454
…
next ›
last »